- Home
- FOXX vs IBIO Comparison
FOXX vs IBIO Comparison
Compare FOXX & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOXX | IBIO |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 16.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FOXX | IBIO |
|---|---|---|
| Price | $4.31 | $2.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 74.7K | ★ 8.8M |
| Earning Date | 02-13-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $63,030,415.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 139.29 | ★ 185.71 |
| 52 Week Low | $1.71 | $0.56 |
| 52 Week High | $11.00 | $6.89 |
Technical Indicators
Market Signals| Indicator | FOXX | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 63.01 |
| Support Level | $4.00 | $1.98 |
| Resistance Level | $4.87 | $2.68 |
| Average True Range (ATR) | 0.54 | 0.23 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 55.10 | 63.27 |
Price Performance
Historical ComparisonAbout FOXX Foxx Development Holdings Inc.
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.